neutral
metalloaminopeptidas
apn
catalyz
cleavag
neutral
basic
amino
acid
nterminu
protein
peptid
substrat
apn
express
dysregul
inflammatori
diseas
well
sever
type
cancer
therefor
inhibitor
apn
may
effect
cancer
inflamm
virtual
screen
enzymat
assay
identifi
three
noncompetit
inhibitor
porcin
human
apn
k
valu
mm
rang
nonpeptid
compound
lack
classic
zincbind
group
zbg
present
apn
inhibitor
molecular
dock
simul
suggest
novel
inhibitor
suppress
apn
activ
altern
mechan
zn
coordin
interact
residu
compris
subsit
apn
note
compound
also
inhibit
porcin
aminopeptidas
papa
use
competit
inhibit
mode
indic
differ
bind
mode
compound
apn
apa
base
sequenc
structur
analys
predict
signific
target
human
apn
residu
improv
select
identifi
compound
remark
intraperiton
inject
compound
inhibit
apn
activ
rat
brain
liver
kidney
indic
good
biodistribut
inhibitor
vivo
data
reinforc
idea
design
novel
apn
inhibitor
base
lead
compound
without
zbg
mammalian
neutral
aminopeptidas
apn
play
pivot
role
mani
physiolog
process
pain
sensat
blood
pressur
regul
tumor
angiogenesi
metastasi
immun
cell
chemotaxi
sperm
motil
cellcel
adhes
coronaviru
entri
accordingli
apn
major
target
treatment
diseas
relat
physiolog
process
apn
extens
studi
member
zincdepend
aminopeptidas
enzym
wide
express
cell
surfac
tissu
intestin
epithelia
nervou
system
apn
type
ii
membran
protein
gener
found
homodim
sever
mammalian
speci
fulllength
human
apn
consist
amino
acid
short
ntermin
cytoplasm
domain
singl
transmembran
segment
larg
ectodomain
contain
two
catalyt
motif
highli
conserv
across
famili
zincbind
motif
exopeptidas
signatur
gxmen
gener
catalyt
mechan
mammalian
apn
believ
similar
prototyp
zinc
peptidas
thermolysin
involv
catalyt
water
attack
scissil
peptid
bond
howev
mean
substrat
gain
access
catalyt
site
product
releas
subject
debat
sever
member
famili
apn
preferenti
cleav
neutral
amino
acid
notabl
alanin
n
terminu
peptid
substrat
lead
activationinactiv
extracellular
space
mammalian
apn
oper
ubiquit
peptid
metabol
pathway
play
import
role
pain
sensat
mood
regul
catalyz
metabol
neuropeptid
process
sensori
inform
one
neuropeptid
enkephalin
bind
opioid
receptor
painrelief
moodregul
effect
apn
hydrolys
shorten
vivo
life
enkephalin
apn
moreov
involv
blood
pressur
regul
degrad
vasoconstrict
peptid
angiotensiniii
caus
vasodil
lower
blood
pressur
endogen
apn
inhibitor
substanc
p
block
enkephalindepend
angiotensindepend
pathway
apn
also
overexpress
cell
surfac
almost
major
cancer
form
essenti
tumor
angiogenesi
degrad
angiogen
peptid
natur
apn
inhibitor
bestatin
substrat
analog
apn
demonstr
antitumor
activ
howev
note
gener
inhibitor
often
show
activ
aminopeptidas
famili
resolut
threedimension
structur
human
apn
complex
angiotensiniv
two
peptidomimet
inhibitor
amastatin
bestatin
allow
applic
structurebas
drug
discoveri
approach
screen
novel
inhibitor
studi
identifi
three
noncompetit
inhibitor
human
porcin
apn
combin
virtual
screen
enzymat
assay
nonpeptid
inhibitor
lack
typic
zincbind
group
zbg
present
apn
inhibitor
molecular
dock
simul
suggest
compound
hinder
apn
activ
altern
mechan
zn
coordin
notabl
intraperiton
inject
compound
inhibit
apn
activ
rat
brain
liver
kidney
indic
good
biodistribut
porcin
kidney
kindli
donat
porcin
research
institut
cuba
human
placenta
free
virus
germ
center
placent
histotherapi
institut
oncolog
radiobiolog
cuba
deae
sephacel
sephadex
purchas
amersham
bioscienc
lleuamc
bestatin
sigmaaldrich
lleupna
bachem
inhibitor
identifi
virtual
screen
hitfind
databas
purchas
maybridg
uk
reagent
use
analyt
grade
h
nmr
data
identifi
inhibitor
suppli
provid
includ
supplementari
inform
fig
bidimension
structur
compound
maybridg
hitfind
librari
download
structur
data
file
sdf
format
build
structur
convers
pdbqt
format
perform
open
babel
softwar
dock
simul
conduct
zn
forc
field
implement
softwar
use
target
structur
hapn
amastatin
complex
pdb
code
ten
pose
gener
compound
lleupna
substrat
rank
use
autodock
zn
forc
field
four
bestrank
compound
base
bind
energi
hapn
filter
use
painsremov
web
server
http
cbligandorgpain
exclud
pan
assay
interfer
compound
threedimension
represent
interact
best
rank
pose
hapn
inhibitor
complex
obtain
use
default
paramet
ligplot
softwar
structur
apninhibitorsubstr
complex
gener
superimpos
structur
apnsubstr
apninhibitor
complex
use
salign
routin
implement
model
softwar
analyz
five
mammalian
amino
acid
sequenc
homolog
human
apn
ampnhuman
ampnpig
pig
ampnrat
rat
ampnbovin
bovin
ampnmous
mous
pig
rabbit
rat
bovin
sequenc
share
sequenc
ident
id
human
apn
also
includ
analysi
two
human
acid
aminopeptidas
famili
glutamyl
aminopeptidas
ampehuman
id
endoplasm
reticulum
aminopeptidas
id
multipl
sequenc
align
mammalian
aminopeptidas
perform
use
clustal
w
softwar
multipl
align
manual
pars
analyz
gap
conserv
amino
acid
region
secondari
structur
inform
use
seaview
softwar
microsom
contain
hapn
prepar
human
placenta
placenta
cut
scissor
homogen
mm
trishcl
ph
buffer
mlg
ware
blender
min
c
crude
extract
centrifug
g
c
min
supernat
centrifug
g
c
one
hour
microsom
fraction
sediment
wash
twice
mm
trishcl
ph
nacl
centrifug
final
resuspens
mm
trishcl
ph
triton
buffer
b
use
enzym
activ
assay
porcin
kidney
apn
papn
partial
purifi
porcin
kidney
cortex
briefli
kidney
cortex
dissect
fresh
recent
thaw
porcin
kidney
wash
cold
distil
water
weight
cut
small
piec
scissor
homogen
distil
water
mlg
homogen
crude
extract
treat
triton
solubil
membranebound
protein
centrifug
g
h
c
supernat
extens
dialyz
use
dialysi
membran
da
cut
spectrapor
vs
buffer
b
dialyz
sampl
appli
deaesephacel
column
cm
equilibr
buffer
b
column
wash
retain
compon
elut
stepwis
use
increas
nacl
concentr
buffer
b
linear
flow
rate
cmh
activ
fraction
concentr
ultrafiltr
appli
sephadex
column
cm
equilibr
buffer
b
linear
flow
rate
cmh
activ
fraction
concentr
ultrafiltr
store
use
apn
activ
enzym
partial
purifi
fold
yield
final
specif
activ
umg
supplementari
inform
fig
microsom
porcin
kidney
cortex
glutamyl
aminopeptidas
porcin
aminopeptidas
papa
prepar
describ
human
apn
solubl
porcin
kidney
apn
activ
mgml
measur
describ
tieku
hooper
use
substrat
lleupna
buffer
b
ml
final
volum
assay
releas
pnitroanilin
measur
everi
min
nm
c
use
genesi
uv
kinet
spectromet
thermo
electron
corpor
usa
papa
activ
mgml
microsom
measur
use
buffer
b
mm
cacl
use
substrat
lglupna
papn
vivo
experi
evalu
rat
apn
activ
microsom
prepar
perform
similar
kinet
assay
condit
min
assay
time
ml
volum
assay
well
plate
reader
multiskan
ex
thermo
electron
corpor
shangai
softwar
reaction
kinet
human
placent
aminopeptidas
n
activ
mgml
microsom
measur
use
lleuamc
substrat
buffer
b
final
assay
volum
ml
kinet
assay
run
c
min
well
plate
amc
fluoresc
measur
nm
bandwidth
upon
excit
nm
bandwidth
biotek
fluoromark
spectrofluoromet
inhibitor
prepar
stock
solut
mm
dmso
dilut
buffer
b
obtain
desir
rang
concentr
rule
interfer
inhibitor
activ
assay
absorb
nm
emiss
spectra
upon
excit
nm
determin
inhibitor
produc
interfer
assay
supplementari
inform
fig
effect
inhibitor
determin
quantifi
decreas
papn
hapn
activ
aliquot
preincub
inhibitor
mm
min
c
n
propos
copeland
parallel
effect
bestatin
mm
assay
similar
condit
n
ic
valu
determin
nonlinear
regress
data
doserespons
curv
use
softwar
grafit
substrat
concentr
inhibitori
assay
equal
lower
one
k
valu
avoid
competit
substrat
inhibitor
k
valu
determin
adjust
experiment
data
initi
rate
increas
substrat
concentr
papn
mmoll
lleupna
hapn
mmoll
lleuamc
michaelismenten
hyperbol
model
n
similar
procedur
follow
evalu
effect
inhibitor
papa
activ
preliminari
studi
select
insid
famili
discard
denatur
effect
inhibitor
apn
test
revers
inhibitorenzym
bind
dilut
studi
adapt
procedur
propos
copeland
papn
concentr
concentr
requir
activ
assay
incub
fix
concentr
inhibitor
mm
min
substrat
concentr
equival
k
valu
buffer
b
ad
gener
rapid
dilut
enzymeinhibitor
mixtur
initi
reaction
parallel
control
assay
includ
enzym
submit
similar
condit
dilut
without
inhibitor
revers
system
establish
studi
kinet
mechan
classic
revers
inhibit
vs
hapn
papn
enzym
assay
conduct
increas
substrat
concentr
mm
lleupna
papn
mm
lleuamc
hapn
presenc
mm
maybridg
compound
mm
bestatin
n
enzym
inhibitor
preincub
c
min
attain
equilibrium
data
fit
michaelismenten
model
determin
v
max
app
valu
lineweaverburk
model
diagnosi
mechan
determin
slope
line
inhibitor
concentr
primari
data
two
secondari
plot
use
recommend
copeland
dixon
plot
max
app
function
inhibitor
concentr
determin
ak
valu
x
intercept
b
plot
slope
lineweaverburk
plot
function
inhibitor
concentr
determin
k
valu
x
intercept
combin
inform
two
secondari
plot
allow
determin
inhibitor
dissoci
constant
singl
set
experiment
data
papa
studi
effect
fix
concentr
inhibitor
mm
differ
concentr
substrat
mm
preliminari
identif
kinet
mode
inhibit
wistar
rat
day
old
g
kept
control
light
condit
light
h
fed
ad
libitum
treat
accord
societi
neurosci
usa
recommend
dissolv
salin
use
inhibitor
mgg
bodi
weight
dissolv
ml
salin
salin
alon
inject
intraperiton
rat
sacrif
decapit
h
inject
anim
inhibitor
vehicl
brain
intestin
liver
kidney
pancrea
rapidli
dissect
frozen
dri
ice
kept
c
membran
prepar
c
homogen
organ
potterelvehjem
homogen
wv
buffer
homogen
centrifug
g
min
pellet
resuspend
half
amount
buffer
centrifug
two
supernat
pool
centrifug
g
min
pellet
resuspend
nacl
buffer
recentrifug
describ
pellet
resuspend
buffer
kept
c
assay
apn
activ
protein
concentr
data
repres
mean
sd
valu
anova
follow
tukeykram
posthoc
test
use
determin
statist
signific
individu
mean
vivo
experi
differ
consid
signific
p
identifi
put
ligand
hapn
screen
maybridg
hitfind
databas
zn
softwar
use
target
structur
hapn
amastatin
complex
supplementari
inform
tabl
base
bind
free
energi
hapn
ligand
complex
preliminari
select
four
bestrank
compound
kinet
studi
human
porcin
aminopeptidas
put
ligand
label
hydrophob
compound
low
molecular
weight
gmol
tabl
supplementari
inform
tabl
howev
compound
exclud
assay
base
painsremov
filter
analysi
due
presenc
quinon
structur
moieti
scaffold
structur
contain
hydrogen
bond
acceptor
group
interestingli
analysi
structur
show
two
hydrogen
bond
donor
group
supplementari
inform
tabl
supplementari
inform
fig
doserespons
studi
perform
identifi
rang
effect
inhibitor
concentr
activ
papn
hapn
enzymat
assay
bestatin
includ
control
substrat
concentr
assay
equival
k
valu
mm
papn
mm
hapn
dose
depend
revers
inhibit
obtain
inhibitor
see
concav
curv
fig
use
preincub
step
min
reach
equilibrium
similar
inhibit
profil
obtain
use
two
differ
substrat
method
detect
ic
valu
rang
mm
papn
mm
hapn
fig
result
dilut
approach
test
revers
fold
drop
inhibitor
concentr
ic
valu
increas
residu
activ
papn
fraction
control
assay
initi
rate
compar
residu
activ
rang
standard
assay
supplementari
inform
tabl
revers
system
establish
indic
specif
inhibit
apn
kinet
mechanist
approach
follow
determin
strength
type
inhibit
compound
porcin
aminopeptidas
activ
michaelismenten
model
lineweaverburk
approxim
use
fig
a
respect
detail
fit
mathemat
model
shown
supplementari
inform
tabl
pattern
straight
line
doublereciproc
plot
repres
signatur
typic
noncompetit
inhibit
profil
inhibitor
impli
inhibitor
display
bind
affin
free
enzym
enzymesubstr
binari
complex
suggest
compet
substrat
bind
free
enzym
remark
line
intersect
x
axe
neg
valu
posit
valu
indic
inhibitor
decreas
affin
enzym
substrat
signatur
fig
mode
inhibit
also
refer
mix
inhibit
base
effect
increas
inhibitor
concentr
v
max
k
valu
similar
inhibit
profil
obtain
interact
compound
hapn
data
shown
secondari
plot
use
k
ak
determin
shown
supplementari
inform
fig
tabl
similar
k
valu
vs
hapn
also
observ
tabl
chelat
zinc
ion
zbg
common
mode
action
inhibitor
target
aminopeptidas
studi
identifi
apn
inhibitor
chemic
structur
contain
classic
zbg
figur
molecul
inhibit
human
porcin
neutral
aminopeptidas
analyz
bind
mode
inhibitor
human
apn
obtain
molecular
dock
simul
observ
remark
preval
hydrophob
interact
aliphat
aromat
polar
residu
fig
compound
coordin
zinc
ion
activ
site
establish
hydrophob
interact
metal
coordin
residu
fig
predict
inhibitor
bind
residu
involv
stabil
transit
state
oxyanion
form
hydrophob
interact
compound
establish
hydrophob
interact
key
residu
polar
water
molecul
attack
scissil
peptid
bond
contrari
bestatin
predict
interact
identifi
inhibitor
residu
fig
except
residu
associ
step
catalysi
mechan
aminopeptidas
understand
noncompetit
inhibit
profil
critic
address
inhibitor
interact
residu
enrol
substrat
bind
pocket
put
subsit
therefor
dock
substrat
activ
site
hapn
subsequ
align
structur
apn
substrat
complex
apn
inhibitor
complex
gener
ternari
apn
inhibitorsubstr
complex
fig
remark
predict
none
compound
interact
residu
belong
substrat
bind
site
leav
unoccupi
space
allow
inhibitor
substrat
bind
enzym
time
fig
analysi
structur
enzymeinhibitorsubstr
complex
reveal
inhibitorenzym
interact
span
residu
compris
among
subsit
substrat
interact
subsit
fig
differ
enzym
bind
mode
new
inhibitor
substrat
explain
noncompetit
inhibit
profil
thu
predict
compound
establish
interact
residu
share
substrat
obtain
preliminari
inform
specif
test
inhibitor
papa
anoth
wellestablish
therapeut
target
famili
observ
inhibit
papa
dosedepend
manner
supplementari
inform
fig
rang
concentr
similar
papn
ic
valu
mm
mm
mm
howev
pattern
straight
line
doublereciproc
plot
obtain
result
preliminari
studi
fix
concentr
inhibitor
increas
concentr
substrat
lglupna
indic
signatur
competit
mode
inhibit
supplementari
inform
fig
analysi
sequenc
aminopeptidas
famili
suggest
target
residu
improv
select
neutral
aminopeptidas
inhibitor
fig
effect
inhibitor
activ
apn
variou
tissu
rat
evalu
vivo
chose
anim
model
due
strong
conserv
inhibitor
interact
residu
within
mammalian
neutral
aminopeptidas
supplementari
inform
fig
intraperiton
inject
mg
g
bw
either
compound
induc
mortal
chang
rat
spontan
behavior
compar
vehicl
group
shown
inject
decreas
apn
activ
brain
liver
kidney
min
later
compar
control
group
salin
inject
anim
compound
also
inhibit
apn
activ
pancrea
fig
aminopeptidas
n
transmembran
proteas
present
wide
varieti
human
tissu
cell
type
endotheli
epitheli
fibroblast
leukocyt
apn
express
dysregul
inflammatori
diseas
well
solid
hematolog
tumor
therefor
inhibitor
apn
may
effect
cancer
inflamm
chelat
zinc
ion
zbg
common
mode
action
neutral
aminopeptidas
inhibitor
inhibitor
display
competit
inhibit
mode
action
identifi
three
noncompetit
inhibitor
human
porcin
neutral
aminopeptidas
ligand
contain
zbg
structur
k
valu
new
compound
similar
report
natur
apn
inhibitor
molecular
dock
simul
predict
inhibitor
bind
site
distinct
occupi
substrat
human
apn
activ
site
fig
consist
noncompetit
inhibit
profil
obtain
kinet
assay
analysi
hapn
inhibitor
complex
show
interact
span
subsit
without
zn
ion
coordin
uncommon
mechan
inhibit
similar
describ
compound
inhibitor
neutral
aminopeptidas
plasmodium
falciparum
newli
identifi
inhibitor
share
compound
high
hydrophob
lack
typic
zbg
lack
zbg
may
diminish
inhibitor
interact
metalloenzym
may
improv
pharmacokinet
oral
color
code
ligand
atom
carbon
magenta
oxygen
red
sulfur
yellow
nitrogen
blue
atom
protein
contact
residu
carbon
blue
light
oxygen
red
nitrogen
blue
zn
atom
gray
hydrogen
bond
interact
repres
red
dot
line
zn
coordin
gray
dot
line
clariti
nt
repres
van
der
waal
interact
ligand
protein
contact
residu
uniprot
code
human
apn
ampnhuman
includ
apn
pig
ampnpig
rat
ampnrat
bovin
ampnbovin
speci
also
includ
analysi
human
glutamyl
ampehuman
endoplasm
reticulum
aminopeptidas
specif
residu
neutral
aminopeptidas
target
inhibitor
highlight
red
rectangl
bioavail
apn
inhibitor
addit
experi
includ
sitedirect
mutagenesi
crystallographi
studi
need
confirm
bind
mode
hapn
inhibitor
complex
check
select
inhibitor
test
activ
porcin
apa
apn
apa
form
interact
main
chain
ntermin
residu
residu
ligand
suggest
two
enzym
share
common
catalyt
mechan
despit
modest
sequenc
similar
howev
pocket
accommod
side
chain
ligand
differ
markedli
apn
apa
consist
differ
substrat
specif
two
enzym
residu
pocket
apn
favor
accommod
bulki
hydrophob
side
chain
convers
pocket
apa
well
suit
accommod
side
chain
acid
residu
carboxyl
side
chain
bound
glutam
form
strong
salt
bridg
hydrogen
bond
energet
favor
interact
consist
high
apa
activ
substrat
glutam
therefor
expect
select
identifi
inhibitor
apn
apa
predict
ligand
target
sever
conserv
residu
preliminari
kinet
experi
confirm
new
compound
also
inhibit
papa
ic
valu
similar
detect
papn
howev
display
competit
inhibit
mode
differ
vs
papn
may
result
accommod
inhibitor
activ
site
papa
differ
bind
mode
predict
apn
addit
experi
clarifi
select
newli
identifi
inhibitor
aminopeptidas
famili
may
identifi
dual
inhibit
biomed
relev
base
sequenc
structur
analys
predict
target
apn
residu
might
use
improv
select
identifi
inhibitor
inhibit
apn
activ
two
compound
rat
brain
kidney
liver
suggest
rapid
absorpt
wide
biodistribut
find
relev
due
implic
apn
physioand
pathophysiolog
process
tissu
mani
hydrophob
drug
revers
bind
site
human
serum
albumin
hsa
associ
improv
pharmacokinet
properti
therapeut
compound
sinc
mammalian
serum
albumin
share
sequenc
ident
similar
function
effect
deliveri
rat
tissu
may
facilit
revers
bind
rat
serum
albumin
hydrophob
site
moreov
hsa
deliveri
system
extens
studi
treat
brain
diseas
sinc
hsa
pass
blood
brain
barrier
interestingli
compound
inhibit
apn
activ
brain
rat
indic
molecul
cross
bloodbrain
barrier
experi
need
confirm
interact
ligand
serum
albumin
identifi
three
noncompetit
inhibitor
human
porcin
apn
ki
valu
mm
rang
combin
virtual
screen
kinet
assay
molecular
dock
simul
suggest
novel
inhibitor
block
apn
activ
altern
mechan
zn
coordin
note
compound
also
inhibit
porcin
aminopeptidas
papa
competit
inhibit
mode
indic
differ
bind
mode
compound
apn
apa
base
sequenc
structur
analys
predict
target
human
apn
residu
fig
vivo
effect
inhibitor
apn
activ
brain
b
kidney
c
liver
pancrea
adult
male
rat
anim
inocul
singl
inject
salin
vehicl
inhibitor
mgg
bw
sacrif
decapit
min
later
tissu
rapidli
dissect
frozen
dri
ice
kept
c
prepar
membran
evalu
apn
activ
describ
materi
method
data
mean
sd
n
anova
data
brain
f
p
kidney
f
p
liver
f
p
pancrea
f
p
tukeykram
posthoc
test
p
p
p
may
lead
design
select
apn
inhibitor
remark
compound
inhibit
apn
activ
brain
liver
kidney
rat
indic
good
biodistribut
vivo
compound
seem
promis
lead
among
identifi
inhibitor
due
clogp
work
reinforc
recent
idea
design
novel
apn
inhibitor
base
lead
compound
without
zbg
author
declar
compet
financi
interest
